

PFC CONSULTING LIMITED (PFCL)
(A wholly owned subsidiary of PFC Limited)
Corporate Office: 9th Floor (A Wing) Statesman House, Connaught Place, New Delhi-110001, Fax: 011-23443990

Notice Inviting Tender (e-bidding only)

Electronic Bids are invited through Open Tender from Firms for "Appointment of Advanced Metering Infrastructure (AMI) Service Provider for Implementation of Smart Metering in Union Territory (UT) of Puducherry". The last date of Bid submission will be 17.01.2022 at 15:00 hrs (IST).

For details visit our website www.pfcindia.com under the head 'tenders' or e-Procurement Portal www.msstcecommerce.com/eprochome/pfccl

"IMPORTANT"

Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.

CENTRAL UNIVERSITY OF HARYANA
NAAC Accredited 'A' Grade University
MAHENDERGARH - 123031 (HARYANA)

ADMISSION NOTICE (2021-22) SPECIAL DRIVE

Central University of Haryana, Mahendragarh is going to organize a special Drive for Admission (Open Counselling in Offline/ Physical mode) against vacant seats in various Undergraduate, Postgraduate and Integrated Programmes of the University on **December 10, 2021** for the Academic Session 2021-22. For detailed information please visit University website www.cuh.ac.in

REGISTRAR

VIVO BIO TECH LIMITED

Regd. Off: B-2-672/5&6, 3rd Floor, Ilyas Mohammed Khan Estate Road No.1, Banjara Hills Hyderabad, Telangana State, India. Ph.No. 040-23313288
Email ID: investors@vivobio.com; website: www.vivobio.com
CIN: L65993TG1987PLC007163

NOTICE OF POSTAL BALLOT

Notice is hereby given pursuant to Section 108, Section 110 and all other applicable provisions, if any, of the Companies Act, 2013 ("the Act") read with Rule 20 and 22 of the Companies (Management and Administration) Rules, 2014, read with General Circular No. 14/2020 dated April 8, 2020, the General Circular No. 17/2020 dated April 13, 2020, the General Circular No. 22/2020 dated June 15, 2020, the General Circular No. 33/2020 dated September 28, 2020, the General Circular No. 39/2020 dated December 31, 2020 and the General Circular No. 10/2021 dated June 23, 2021 issued by Ministry of Corporate Affairs ("MCA Circulars"), read with Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standards on General Meetings (SS-2) including any statutory modification or re-enactment thereof for the time being in force and pursuant to other applicable laws and regulations, that the Resolutions are proposed to be passed by the Members of the Company through postal ballot by remote e-voting process ("E-Voting") for seeking approval of Members of the Company for (i) Appointment of Dr. Sankaranarayanan Alangudi (DIN: 02703392) as Whole Time Director of the Company for a period of 5 years i.e., from 6th January, 2022 to 5th January, 2027; (ii) Appointment of Mr. K. Sri Kalyan (DIN: 03137506) as Whole Time Director for a period of 5 years i.e., from 3rd November, 2021 to 2nd November, 2026; (iii) Shifting of Registered Office from B-2-672/5&6, 3rd Floor, Ilyas Mohammed Khan Estate Road no.1, Banjara Hills Hyderabad to Survey # 349/A, Pregarur Village, Gajwel - 502311, Siddipet District, Telangana, India with effect from 6th January, 2022; (iv) To approve the revision in remuneration of Mr. Viswanath Kempella, advisor from the financial year 2021-22 and (v) To approve the Sale of Company Land to M/s. Vivobio Discovery Services Private Limited (Wholly Owned Subsidiary) or such other Company as detailed in the Notice of Postal Ballot dated 2nd December, 2021.

On Monday, the 6th December, 2021, the Company has sent the Notice of Postal Ballot along with the Login ID and password to the Members for e-voting who have registered their e-mail IDs with Depository Participant(s) or with the Company; The Board of Directors of the Company has appointed Mr. G. Vinay Babu (ACS: 20592 and CP: 20707), Practising Company Secretary as the Scrutinizer for conducting the Postal Ballot process.

Members are requested to provide their assent or dissent through e-voting only. The Company has appointed Central Depository Services (India) Limited (CDSL) for providing e-voting facility to enable the Members to cast their votes electronically. The detailed procedure for e-voting is provided in the Notice of Postal Ballot. Members are requested to note that the e-voting shall commence from 9:00 AM (IST) on Wednesday, 8th December, 2021 and ends on 5:00 PM (IST) on Thursday, 6th January, 2022. The e-voting module shall be disabled by CDSL for voting thereafter.

In accordance with the above mentioned Circulars, physical copies of the Notice of Postal Ballot along with Postal Ballot Forms and Pre-paid Business Reply Envelope will not be sent to the Members. The communication of the assent or dissent of the Members would take place through the remote e-voting system only.

The voting rights of Members shall be reckoned as on Friday, 3rd December, 2021 which is the cut-off date. A person who becomes a Member after the Cut-off date shall treat this notice for information purpose only. The copy of the Postal Ballot Notice is available on the Company's website at www.vivobio.com, website of the Stock Exchange i.e., BSE Limited at www.bseindia.com and on the website of CDSL at <https://www.evotingindia.com/>. Members who have not received the Postal Ballot Notice may download it from the above mentioned websites or write to the Company at investors@vivobio.com. Please note that the voting beyond 5:00 PM (IST) on Thursday, 6th January, 2022 will not be valid and also shall not be allowed beyond the said date.

Members holding shares in physical mode and who have not updated their email addresses with the Company are requested to update their email addresses by writing to the Company or RTA at investors@vivobio.com or info@aarthicconsultants.com along with the copy of the signed request letter mentioning the name and address of the Member, self-attested copy of the PAN card and self-attested copy of any document i.e., Driving License or Election Identity Card or Passport or Aadhar Card in support of the address of the Member. Members holding shares in dematerialised mode are requested to register / update their email addresses with the Depository Participants with whom they are maintaining Demat Accounts. In case of any queries / difficulties in registering the e-mail address, Members may write to investors@vivobio.com.

The resolution if approved shall be deemed to have been passed on the last date of e-voting i.e., Thursday, 6th January, 2022. The result of Postal ballot e-voting will be announced on or before Saturday, 8th January, 2022 and will be displayed on the Company's Website <https://www.vivobio.com> and communicated to BSE Limited. The Company will also display the results of Postal Ballot at its Registered Office.

Mr. A. Karthik, Company Secretary, VIVO Bio Tech Limited, Regd. Off: B-2-672/5 & 6, 3rd Floor, Ilyas Mohammed Khan Estate Road No.1, Banjara Hills, Hyderabad, Telangana State, India, email: investors@vivobio.com, Ph. No. 040-23313288, is responsible to address the grievances connected with the E-voting and Postal Ballot.

By order of the Board
For VIVO Bio Tech Limited
Sd/-
A. Karthik
Company Secretary
M.No: A44462

Place: Hyderabad
Date: 06.12.2021

NATIONAL SEEDS CORPORATION LTD.
(A Government of India Undertaking)
Regional Office: Lucknow
Lakshmi Plaza, 4th Floor, INS-19, Sector 7C, Vrindavan Yojna, Amar Shaheed Path, Lucknow-226 029 (UP), Ph No. 0522-7118213, 3516971

No. III -3(4)/Paddy CS-Source/MKG/NSC-LKO/2021-22 Dated 04.12.2021

E-Tender for Purchase of Paddy CS

National Seeds Corporation Ltd., Regional Office Lucknow invites e-tender for purchasing Paddy (Certified Seed of varieties MTU-7029 (6000 qtls), BFT-5204 (6000 qtls), NDR-359 (1000 qtls) & Sarju-52 (3000 qtls). The tender is to be submitted up to 28.12.2021. For details, visit website www.india.seeds.com, eprocure.gov.in, india.seeds.eproc.in. For any changes regarding date, qty etc the same will be updated on NSC website.

Regional Manager Lucknow

ISMT Limited

Regd. Office: Panama House (Earlier known as Lunkad Towers), Viman Nagar, Pune - 411 014
Ph : 020-41434100 Fax : 020-26630779 E-mail : secretarial@ismt.co.in Website : www.ismt.co.in
CIN : L27109PN1999PLC016417

EXTRACT OF THE STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE PERIOD ENDED SEPTEMBER 30, 2021

Sr. No.	Particulars	Quarter ended September 30, 2021	Quarter ended September 30, 2020	Half Year ended September 30, 2021	Year ended March 31, 2021
		Unaudited		Audited	
1	Total Income	573.61	310.92	1,054.69	1299.62
2	Net Profit/ (Loss) for the period (before tax, Exceptional items)	(47.26)	(74.03)	(103.51)	(292.98)
3	Net Profit/ (Loss) for the period before tax (after Exceptional items)	(47.54)	(67.89)	(103.25)	(342.42)
4	Net Profit/ (Loss) for the period after tax (after Exceptional items)	(47.54)	(67.89)	(103.27)	(342.52)
5	Total Comprehensive Income for the period [Comprising Profit/ (Loss) for the period (after tax) & Other Comprehensive Income (after tax)]	(51.31)	(67.57)	(106.48)	(343.55)
6	Paid-up Equity Share Capital (Face value of Rs. 5/- per share)	73.25	73.25	73.25	73.25
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	(1,725.37)
8	Earnings per share (of Rs. 5/- each) Basic and Diluted (Rs.)	(3.25)	(4.63)	(7.05)	(23.38)

Notes:
1. Additional information on standalone financial results is as follows:

Particulars	Quarter ended September 30, 2021	Quarter ended September 30, 2020	Half Year ended September 30, 2021	Year ended March 31, 2021
Revenue from Operations	564.40	297.28	1041.53	1234.67
Profit before tax	(52.67)	(68.96)	(106.86)	(350.61)
Profit after tax	(52.67)	(68.96)	(106.79)	(350.71)

2. The above is an extract of the Consolidated Financial Results filed with Stock Exchanges under Reg 33 of the SEBI (LODR) Regulations, 2015. Full format of the Standalone & Consolidated Financial Results are available on websites of Stock Exchanges (www.nseindia.com) and on Company's website (www.ismt.co.in).

3. Auditors have qualified Financial Results in respect of Investment in & receivables from a Subsidiary Company, Recoverability of amounts from Maharashtra State Electricity Distribution Company Ltd, Minimum Alternate Tax, non-provision of overdue/ penal & compounding of interest on loans, inability to determine recoverable value of Captive Power Plant. Details of the same forms part of Financial Results available on aforesaid websites.

4. The above results have been prepared in accordance with Companies (Indian Accounting Standards) Rules, 2015 (Ind AS).

5. The above results have been reviewed by the Audit Committee & approved by the Board of Directors at their respective meetings held on December 06, 2021.

For ISMT Limited
Rajiv Goel
Chief Financial Officer

Place : Pune
Date : December 06, 2021

DRS DILIP ROADLINES LIMITED

CIN: L60231TG2009PLC064326
Regd. Off: 306, Kabra Complex, 61, MG Road Secunderabad 500 003
Phone: 040 27711504, 040 27711276
Email: info@drsindia.in; website: www.drsindia.in

NOTICE

Notice is hereby given that the 12th Annual General Meeting (AGM) of the Company will be held on **Thursday, 30th December, 2021 at 11:00 A.M at 2nd Floor, Kabra Complex, 61, M G Road, Secunderabad 500003.** Notice of the said AGM, E-Voting instructions etc., forming part of Annual Report for the financial year 2020-21 have been sent to the members of the Company electronically whose e-mail IDs are registered with the Depositories and in physical mode to all the other members at their registered addresses. The dispatch / e-mail transmission of Annual Reports has been completed on 6th December, 2021. The copies of aforesaid documents are available on the website and for inspection at the registered office of the Company during the office hours.

Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of Companies (Management and Administration) Rules, 2014, as amended, and Regulation 44 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, the Company is offering e-voting facility to its members in respect of all the items of business to be transacted at the ensuing AGM. The members may transact the said business through voting by electronic means. The Company has engaged Central Depository Services (India) Limited as the authorized agency to provide the e-voting facility.

The remote e-voting facility will commence on Monday, 27th December, 2021 at 09:00 A.M and close on Wednesday, 29th December 2021 at 05:00 PM (both days inclusive) and shall not be available thereafter. The remote e-voting shall not be allowed after the said date and time and the e-voting module shall be disabled for voting thereafter. During this period, only a person whose name is recorded in the Register of members or Register of beneficial owners maintained by the Depositories as on the cut-off date, i.e., 23rd December, 2021, shall be entitled to avail the facility of remote e-voting / voting in the AGM. The voting rights of the members for e-voting and for physical voting at the meeting shall be in proportionate to their shareholding in the paid up equity share capital of the Company as on the said cut-off date.

Any person who acquires shares of the Company and becomes its member after the dispatch of the notice and also holds shares as on cut-off date may cast his vote by remote e-voting / voting in the AGM. Further, if already registered with CDSL for remote e-voting then you can use existing User ID and Password for casting your vote. You may also approach the Company for required assistance in connection with generation of User ID / Password in order to exercise your right to vote.

Facility of voting through Physical Ballot is being made available at the AGM. Members attending the meeting, who have not already cast their vote by remote e-voting may exercise their right at the meeting. A member who has cast his vote by remote e-voting may participate in the AGM even after exercising his right to vote through remote e-voting but shall not be allowed to vote at the meeting.

The notice of the Annual General Meeting along with e-voting instructions, forming part of the Annual Report for the financial year 2020-21 are available on the Company's website <https://www.drsindia.in> and also on the website of CDSL, www.cdslindia.com. Members are requested to refer e-voting instructions contained in the 12th Annual Report of the Company, regarding the process and manner for e-voting by electronic means.

For any query or grievance, members may contact CDSL at Toll free No. 18002005533 or write an e-mail to helpdesk.evoting@india.com or contact the Company Secretary & Compliance Officer, Mr. T.Siva Rama Krishna, at the Registered office address of the Company, or call at 040 23817299 or write an email to investors@drsindia.in

For DRS DilipRoadlines Limited
Sd/-
Anjani Kumar Agarwal
CEO & Managing Director

Date: 06.12.2021
Place: Hyderabad

arrive at a conclusion not an assumption.
Inform your opinion with detailed analysis.

The Indian Express. For the Indian Intelligent.

...continued from previous page.

In case of any revision in the Price Band, the Bid/ Offer Period will be extended by at least three additional Working Days after such revision in the Price Band, subject to the Bid/ Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company and the Investor Selling Shareholder, in consultation with the BRLMs, for reasons to be recorded in writing, extend the Bid/ Offer Period for a minimum of three Working Days, subject to the Bid/ Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/ Offer Period, if applicable, shall be widely disseminated by notification to BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE"), and together with BSE, the "Stock Exchanges", by issuing a public notice, and also by indicating the change on the respective websites of the BRLMs and at the terminals of the Syndicate Members and by intimation to the Designated Intermediaries and the Sponsor Bank, as applicable.

The Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 31 of the SEBI ICDR Regulations. This Offer is in compliance with Regulation 6(1) of the SEBI ICDR Regulations wherein not more than 50% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers ("QIBs") and such portion the "QIB Portion" provided that our Company and the Investor Selling Shareholder, in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price, in accordance with the SEBI ICDR Regulations. In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs (other than Anchor Investors) including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 35% of the Net Offer shall be available for allocation to Retail Individual Bidders ("RIB") in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. Further, up to [x] Equity Shares aggregating up to ₹ 50 million will be available for allocation to Eligible Employees, subject to valid Bids being received at or above the Offer Price. All Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective ASBA accounts and UPI ID (in case of RIBs using the UPI Mechanism), in which case the corresponding Bid Amounts will be blocked by the SCSBs or under the UPI Mechanism, as applicable to participate in the Offer. Anchor Investors are not permitted to participate in the Anchor Investor Portion of the Offer through the ASBA process. For details, see "Offer Procedure" on page 338 of the RHP.

Bidders/Applicants should ensure that DP ID, PAN, Client ID and UPI ID (for RIBs bidding through the UPI mechanism) are correctly filled in the Bid cum Application Form. The DP ID, PAN and Client ID provided in the Bid cum Application Form should match with the DP ID, PAN, Client ID available in the Depository database, otherwise, the Bid cum Application Form is liable to be rejected. Bidders/Applicants should ensure that the beneficiary account provided in the Bid cum Application Form is active. Bidders/Applicants should note that on the basis of the PAN, DP ID, Client ID and UPI ID (for RIBs bidding through the UPI mechanism) as provided in the Bid cum Application Form, the Bidder/Applicant may be deemed to have authorised the Depositories to provide to the Registrar to the Offer, any requested Demographic Details of the Bidder/Applicant as available on the records of the depositories. These Demographic Details may be used, among other things, for giving Allotment Advice or unblocking of ASBA Account or for other correspondence(s) related to the Offer. Bidders/Applicants are advised to update any changes to their Demographic Details as available in the records of the Depository Participant to ensure accuracy of records. Any delay resulting from failure to update the Demographic Details would be at the Bidders/Applicants' sole risk. Investors must ensure that their PAN is linked with Aadhaar and are in compliance with CBDT

notification dated Feb 13, 2020 and press release dated June 25, 2021.

Contents of the Memorandum of Association of the Company as regards its objects: For information on the main objects of the Company, please see the section "History and Certain Corporate Matters" on page 169 of the RHP. The Memorandum of Association of the Company is a material document for inspection in relation to the Offer. For further details, please see the section entitled "Material Contracts and Documents for Inspection" on page 363 of the RHP.

Liability of the members of the Company: Limited by shares

Amount of share capital of the Company and Capital structure: As on the date of the RHP, the authorised share capital of the Company is ₹ 541,766,000 divided into 270,883,000 Equity Shares of face value of ₹2 each. The issued, subscribed and paid-up share capital of the Company is ₹ 223,522,330 divided into 111,761,165 Equity Shares of face value of ₹2 each. For details, please see the section entitled "Capital Structure" beginning on page 74 of the RHP.

Names of signatories to the Memorandum of Association of the Company and the number of Equity Shares subscribed by them: Gangadi Madhukar Reddy and Cherukupalli Bhaskar Reddy were the initial signatories to the Memorandum of Association of our Company pursuant to the subscription of 9,900 Equity Shares and 100 Equity Shares bearing face value of 10 each, respectively. For details of the share capital history and capital structure of our Company, please see the section entitled "Capital Structure" beginning on page 74 of the RHP.

Listing: The Equity Shares to be Allotted through the Red Herring Prospectus are proposed to be listed on the Stock Exchanges. Our Company has received 'in-principle' approvals from BSE and NSE for the listing of the Equity Shares pursuant to their letters dated September 2, 2021 and September 1, 2021, respectively. For the purposes of the Offer, the Designated Stock Exchange shall be BSE. A signed copy of the Red Herring Prospectus and the Prospectus shall be delivered to the RoC in accordance with Sections 26(4) and 32 of the Companies Act, 2013. For details of the material contracts and documents available for inspection from the date of the Red Herring Prospectus up to the Bid/ Offer Closing Date, see "Material Contracts and Documents for Inspection" on page 363 of the RHP.

Disclaimer Clause of the SEBI: SEBI only gives its observations on the offer documents and this does not constitute approval of either the Offer or the specified securities or the offer document. The investors are advised to refer to page 317 of the RHP for the full text of the disclaimer clause of SEBI.

Disclaimer Clause of NSE: It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Offer Document has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the Offer Document. The investors are advised to refer to page 320 of the RHP for the full text of the disclaimer clause of NSE.

Disclaimer Clause of BSE (Designated Stock Exchange): It is to be distinctly understood that the permission given by BSE should not in any way be deemed or construed that the RHP has been cleared or approved by BSE nor does it certify the correctness or completeness of any of the contents of the RHP. The investors are advised to refer to page 319 of the RHP for the full text of the disclaimer clause of BSE.

General Risks: Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have not been recommended or approved by the SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of this Red Herring Prospectus. Specific attention of the investors is invited to "Risk Factors" on page 30 of the RHP.

ASBA # Simple, Safe, Smart way of Application!!!

Applications supported by blocked amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account. For further details, check section on ASBA below.
Mandatory in public issues. No cheque will be accepted.

UPI-Now available in ASBA for Retail Individual Investors ("RIIs") applying through Registered Brokers, DPs and RTAs. RIIs also have the option to submit the application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account. Investors are required to ensure that the bank account used for bidding is linked to their PAN. Bidders must ensure that their PAN is linked with Aadhaar and are in compliance with CBDT notification dated February 13, 2020 and press release dated June 25, 2021

ASBA has to be availed by all the investors except anchor investors. UPI may be availed by Retail Individual Bidders. For details on the ASBA and UPI process, please refer to the details given in ASBA form and abridged prospectus and also please refer to the section "Offer Procedure" on page 338 of the RHP. The process is also available on the website of Association of Investment Bankers of India ("AIBI") and Stock Exchanges and in the General Information Document. ASBA bid-cum-application forms can be downloaded from the websites of Stock Exchanges and can be obtained from the list of banks that is displayed on the website of Securities and Exchange Board of India ("SEBI") at www.sebi.gov.in. For the list of UPI apps and banks live on IPO, please refer to the link: www.sebi.gov.in. RIBs Bidding using the UPI mechanism may apply through the SCSBs and mobile applications whose names appear on the website of SEBI, as updated from time to time. Axis Bank Limited has been appointed as Sponsor Bank for the Offer, in accordance with the requirements of the SEBI Circular dated November 1, 2018 as amended. For offer related queries, please contact the BRLMs on their respective email IDs as mentioned below. For UPI related queries, investors can contact NPCI at the toll free number: 18001201740 and mail id: ipo.upi@npci.org.in.

BOOK RUNNING LEAD MANAGERS

AXIS CAPITAL Axis Capital Limited 1 st Floor, Axis House, C-2, Wadia International Centre, P.B. Marg, Worli, Mumbai - 400 025, Maharashtra, India Tel: +91 22 4325 2183 E-mail: medplus.ipo@axiscap.in Investor grievance e-mail: complaints@axiscap.in Website: www.axiscapital.co.in Contact person: Pratik Pednekar SEBI Registration No: INM000012029	CREDIT SUISSE Credit Suisse Securities (India) Private Limited 6 th Floor, Ceejay House, Plot F, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai - 400 018 Tel: +91 22 6777 3885 E-mail: list.medplusipo@credit-suisse.com Investor Grievance e-mail: list.igcellmer-brnkg@credit-suisse.com Website: www.credit-suisse.com Contact person: Abhishek Joshi SEBI Registration No.: INM000011161	Edelweiss Edelweiss Financial Services Limited 6 th Floor, Edelweiss House, Off C.S.T. Road, Kalina Mumbai - 400 098, Maharashtra, India Tel: +91 22 4009 4400 E-mail: medplus.ipo@edelweissfn.com Investor grievance e-mail: customerservice.mb@edelweissfn.com Website: www.edelweissfn.com Contact person: Dhruv Bhavsar SEBI Registration No.: INM0000010650	NOMURA Nomura Financial Advisory and Securities (India) Private Limited Ceejay House, Level 11 Plot F, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai - 400 018, Maharashtra, India Tel: +91 22 4037 4037 E-mail: medplusipo@nomura.com Investor grievance e-mail: investorgrievance-in@nomura.com Website: www.nomuraholdings.com/company/group/asia/ Contact person: Vishal Kanjani / Chirag Shah SEBI Registration No: INM000011419	FINTECH KFin Technologies Private Limited Selenium, Tower B, Plot No- 31 and 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddy 500 032, Telangana, India Tel: +91 40 6716 2222/ 180034 54001 E-mail: medplus.ipo@kfinfintech.com Investor grievance e-mail: einward.ris@kfinfintech.com Website: www.kfintech.com Contact person: M. Murali Krishna SEBI Registration No.: INR000000221	COMPANY SECRETARY AND COMPLIANCE OFFICER Parag Jain 707, 7th Floor, 5-9-13, Taramandal Commercial Complex, Saifabad, Hyderabad - 500 004, Telangana, India. Tel: +91 040 6724 6724 E-mail: cs@medplusindia.com Investors may contact the Company Secretary and Compliance Officer or the Registrar to the Offer in case of any pre-Offer or post-Offer related grievances including non-receipt of letters of Allotment, non-credit of Allotted Equity Shares in the respective beneficiary account, non-credit of refund orders or non-credit of funds by electronic mode, etc. For all Offer related queries and for redressal of complaints, Investors may also write to the BRLMs.
---	---	--	---	---	--

AVAILABILITY OF THE RHP: Investors are advised to refer to the RHP and the "Risk Factors" beginning on page 30 of the RHP, before applying in the Offer. A copy of the RHP is available on website of SEBI at www.sebi.gov.in and is available on the websites of the BRLMs, i.e. Axis Capital Limited, Credit Suisse Securities (India) Private Limited, Edelweiss Financial Services Limited and Nomura Financial Advisory and Securities (India) Private Limited at www.axiscapital.co.in, www.credit-suisse.com, www.edelweissfn.com and www.nomuraholdings.com/company/group/asia/india/index.html, respectively, and is available on the websites of the BRLMs, i.e. Axis Capital Limited, Credit Suisse Securities (India) Private Limited, Edelweiss Financial Services Limited and Nomura Financial Advisory and Securities (India) Private Limited at www.axiscapital.co.in, www.credit-suisse.com, www.edelweissfn.com and www.nomuraholdings.com/company/group/asia/india/index.html, respectively. Investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please see the section entitled "Risk Factors" on page 30 of the RHP. Potential investors should not rely on the DRHP filed with SEBI for making any investment decision and such investment decision must be made solely on the basis of the Red Herring Prospectus once filed with the RoC.

The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended ("U.S. Securities Act"), or any state law of the United States and, unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold (i) within the United States only to persons reasonably believed to be "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act) pursuant to Section 4(a) of the U.S. Securities Act, and (ii) outside the United States in offshore transactions as defined in and in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales are made. There will be no public offering of the Equity Shares in the United States.

For MEDPLUS HEALTH SERVICES LIMITED
On behalf of the Board of Directors
Sd/-
Company Secretary and Compliance Officer

MEDPLUS HEALTH SERVICES LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the RHP with RoC. The RHP shall be available on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com, respectively, and is available on the websites of the BRLMs, i.e. Axis Capital Limited, Credit Suisse Securities (India) Private Limited, Edelweiss Financial Services Limited and Nomura Financial Advisory and Securities (India) Private Limited at www.axiscapital.co.in, www.credit-suisse.com, www.edelweissfn.com and www.nomuraholdings.com/company/group/asia/india/index.html, respectively. Investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please see the section entitled "Risk Factors" on page 30 of the RHP. Potential investors should not rely on the DRHP filed with SEBI for making any investment decision and such investment decision must be made solely on the basis of the Red Herring Prospectus once filed with the RoC.

The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended ("U.S. Securities Act"), or any state law of the United States and, unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold (i) within the United States only to persons reasonably believed to be "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act) pursuant to Section 4(a) of the U.S. Securities Act, and (ii) outside the United States in offshore transactions as defined in and in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales are made. There will be no public offering of the Equity Shares in the United States.